Custom-Made cancer vaccine enters early human testing
NCT ID NCT07583953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and be receiving standard cancer therapy. This is an early-stage trial, so the main focus is safety, not yet proving the vaccine cures cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?